Elizabeth Dudnik

Excellent presentation by @DrMarkAwad of exploratory neoadj nivo-ipi arm vs chemo of #cm816. Improved pCR, EFS and trend toward improved OS. Striking early crossing of EFS curves suggests chemo is still needed in this setting.

#ESMO23 Dr. @DoctorJSpicer presents OS data from KEYNOTE 671: neoadjuvant pembrolizumab + chemotherapy followed by surgery and adjuvant pembro x 1 year. Perioperative IO improves survival. OS HR 0.72, 3y OS rate 71% vs 64%, impressive tails. Now an FDA approved standard.

#ESMO23 RR 63% with pembrolizumab + adagrasib in PDL1 high NSCLC. Median time to response 1.4m. mDOR and mPFS not yet reached. Single arm study but recall RR with pembro in KEYNOTE 024 was 44.8%. Certainly warrants a phase III study.

#ESMO23 Included 54 pts with PD-L1 high NSCLC. Balanced arms. Only 6% discontinuation of adagrasib from TRAEs. Treatment related hepatic events in < 10% of adagrasib + pembrolizumab arm. Very reassuring. Why different from sotorasib? PK difference? Binding differences?

#WCLC23 Presidential Session🔥 Incredible presentation by Erik Lim 🇬🇧 of the Ph III MARS2 trial of Surgery v No surgery in mesothelioma: - no OS benefit - poorer QOL - higher toxicity Critical study. Congrats to all authors @iaslc @OncoAlert #LCSM

🚨#WCLC23 Ph3 #FLAURA2 Primary endpoint: 𝐏𝐅𝐒 𝐛𝐲 𝐢𝐧𝐯 ▪️PFS:Osi+chemo 𝘷𝘴. Osi: 25.5 𝘷𝘴. 16.7 HR 0.62; p<0.0001; 51% maturity ▪️OS was immature (27%) HR 0.90; p=0.52 ▪️G ≥3 AEs: 64%/27% A positive study to integrate w/ many Ph3 trials ready to be out in this field

🌟 Combining Stereotactic Ablative Radiotherapy (SABR) with immunotherapy (I-SABR) shows a significant boost in 4-year event-free survival rates, compared to SABR alone. 🔘Fewer relapses, promising safety profile, and a potential game-changer for patients with early-stage NSCLC. 🔘Awaiting further results from ongoing trials for confirmation. 🎗️💊 @TheLancet @OncoAlert @OncBrothers @IASLC #lungcancer #Immunotherapy

Phase III IPSOS trial @TheLancet: first-line atezolizumab (anti-PDL1) monotherapy to single agent chemotherapy in 453 pts ineligible for platinum-doublet (PS 2-3 or age plus comorbidities). QoL and survival favored atezolizumab (HR 0.78, 2y OS 24% vs 12%). thelancet.com/journals/lance…

Astra and Daiichi say that their TROP2 ADC hit on PFS at interim in the anticipated phase 3 NSCLC trial but that OS needs to mature further. No data provided today. astrazeneca.com/media-centre/p…

First snapshots of Aegean data, periadjuvant phase 3 trial in resectable lung cancer. Neoadjuvant chemo-Durva then surgery then adj Durva vs neoadj chemo alone then surgery. Looking forward to digging into these data! Does adj year of PD-L1 blockade add to neoadj alone? #LCSM

Not enough attention has been paid to chronic fatigue and out of hours working amongst health professionals and its impact on their safety and of others- these data do not surprise me - I have heard many stories over 25yrs of fatal accidents likely resulting from night work

Altogether, this suggests a mechanistic and causative link between air pollutants triggering expansion of pre-existing mutant cells in normal tissues via a clinically actionable inflammatory axis. (Thanks @Biorender)

Tumour promotion was first proposed by Berenblum & Shubik and developed by Allan Balmain and others. Thank you to Prof Balmain for this excellent N&V nature.com/articles/d4158…

Today our important study on air pollutants in the promotion of lung cancer has been published in @Nature led by @WillHilliam @LimEmilia @DrClareWeeden @SwantonLab ...Thread below🧵nature.com/articles/s4158…

Amivantamab in EGFR exon20 insertion in Non-small cell lung cancer #NSCLC #lungcancer #ELCC23

#ELCC23 3-yr Update of CM816 trial: Neoadj chemoIO v chemo shows - contd EFS benefit - OS HR 0.67 (p=0.012) - *chemoIO appears to protect against CNS progression* - this is the gold Impressive data. Identifying what further IO adds, is the key quesn @myESMO @FordePatrick #LCSM

CM816 trial 👑: Neoadjuvant chemo + IO improved 3-year EFS vs neoadj Ch alone with lowe 🧠 recurrences with chemoIO approach💡Challenges: Do we need ADJ IO after the neoadj CT+IO approach?Role of this strategy in stage I/II NSCLC? In stage III: CM816 vs PACIFIC? @myESMO #ELCC2023

Die dazugehörige Publikation in Zusammenarbeit mit @AurelieSwalduz @Alfdoc2 @lungendoc @hausruck1 @_SayedHashemi @ElizabethDudnik @lungcancerpall @JairBar4 @ZerAlona und anderen finden Sie unter doi.org/10.1177/175883…

@AMalfettonePhD @MLJohnsonMD2 @OncoAlert @myESMO Indeed, the superiority confirmed. ORR and the lack of OS benefit considering the low cross-over rate is a bit disappointing though..@myESMO

#CodeBreaK200 study for pts with #KRASG12C-mut platinum/IO pretreated #NSCLC 🎯Sotorasib (oral KRASG12C inhibitor) showed superiority over docetaxel! ✅1y-PFS: 24.8 vs 10.1% (HR=0.66; P=0.002) ✅ORR: 28.1 vs 13.2% ⬇️grade≥3 TRAEs Congrats @MLJohnsonMD2 & team! #ESMO22 @OncoAlert

IPSOS: a very important ph 3 randomized study confirming superiority of 1L Atezo over SA Chemo in ECOG PS 2/3 elderly aNSCLC pts- irrespectively of PD-L1 status! New standard for this poor prognosis subset. Congratulations to authors! ⁦@myESMO⁩ #ESMO22